Craig Cook appointed Chief Business Officer and Co-founder at ABILITY Neurotech, the Wyss Geneva’s flagship spin-off
The Wyss Center for Bio and Neuroengineering proudly announces the appointment of Craig Cook, former Head of Business Development & Licensing at the Center, as Chief Business Officer and Co-founder of ABILITY Neurotech SA, a pioneering spin-off company translating breakthrough brain-computer interface (BCI) technology into clinical impact.
Wyss Center for Bio and Neuroengineering Announces Venture with dEEGtal Insight: An Innovative Tool for Early Epilepsy Detection
The Wyss Center is proud to partner with dEEGtal Insight SA with a CHF 750,000 investment in its next stage of growth and development. dEEGtal Insight SA is a pioneering spin-off, of the Geneva University Hospitals (the EEG and Epilepsy Unit) and the University of Geneva, focused on transforming early detection and diagnosis of epilepsy. This forward-thinking initiative leverages advanced AI-powered software to deliver precise and timely insights to neurologists, enabling early intervention and better patient outcomes.
Wyss Center for Bio and Neuroengineering: New Horizons in Neural Recording Systems
A new whitepaper, released by the Wyss Center for Bio and Neuroengineering, reveals the first neural signals recorded by the ABILITY brain-computer interface (BCI) system. It also lays out the plan for a forthcoming human clinical trial with ABILITY to enable communication for people locked-in as a result of brain stem stroke or ALS (amyotrophic lateral sclerosis). The Wyss Center team, together with academic and clinical collaborators and a network of industrial technology partners, is developing ABILITY, a wireless implantable medical device, to improve quality of life and provide independence for people with paralysis.
